Quick Answer
Kymera Therapeutics, Inc. reported Total Assets of $1.74 billion for fiscal year 2025.
Kymera Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $1.74B | +78.2% |
| 2024 | $978.03M | +69.9% |
| 2023 | $575.76M | -4.5% |
| 2022 | $603.13M | -0.5% |
| 2021 | $605.90M | +24.4% |
| 2020 | $487.18M | +317.5% |
| 2019 | $116.70M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.10B | +6.5% | -2.6% |
| June 30, 2025 | $1.13B | +36.9% | +23.2% |
| March 31, 2025 | $918.31M | +5.8% | -6.1% |
| December 31, 2024 | $978.03M | +69.9% | -5.5% |
| September 30, 2024 | $1.03B | +87.3% | +25.3% |
| June 30, 2024 | $826.02M | +41.9% | -4.9% |
| March 31, 2024 | $868.25M | +41.4% | +50.8% |
| December 31, 2023 | $575.76M | -4.5% | +4.2% |
- Kymera Therapeutics, Inc. showed an increase of +78.2% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s total assets has grown by 1393.4% (from $116.70 million to $1.74 billion).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: